Market Overview:
The global liquid tumor biopsy market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The growth in the market can be attributed to factors such as rising incidence of cancer, technological advancements in liquid tumor biopsy, and increasing demand for personalized medicine. However, the high cost of diagnostic procedures may restrain the growth of this market during the forecast period. Based on type, the global liquid tumor biopsy market is segmented into ctDNA and CTC. The ctDNA segment is expected to grow at a higher CAGR than the CTC segment during the forecast period. This can be attributed to increasing use of ctDNA for diagnosis and treatment planning in various cancers. Based on application, the global liquid tumor biopsy market is divided into clinical laboratories and hospitals segments.
Product Definition:
A liquid tumor biopsy is a procedure in which a sample of tumor tissue is collected from the body using a needle. This type of biopsy is often used to diagnose cancer and to determine the best treatment options.
ctDNA:
ctDNA, also known as Cancer DNA or tumor DNA, is the genetic material that contains the information to build a cancerous tumor.
1) The amount of ctDNA varies from one type of tumor to another and depends on various factors such as the stage (how much cancer has spread), grade (how aggressive or malignant it is), and other factors.
CTC:
CTC or Cancer Targeted CTC is a new technology that has been used in Liquid Tumor Biopsy (LTB) market for quite some time. It helps in identification of cancer cells and tissues with high accuracy and precision. The major advantage of this targeted test is that it can only detect the abnormal cells, which are likely to be cancerous, while leaving the normal tissue alone.
Application Insights:
The application segment is segregated into clinical laboratories, hospitals and others. The hospital segment held the largest market share in 2017 owing to availability of advanced healthcare facilities in case of emergencies along with a high volume of tumor biopsies being performed every year.
CTC DNA testing has revolutionized cancer diagnosis by providing clinicians with an accurate molecular pathology assay that can be performed quickly at the bedside, enabling sensitive detection of minimal residual disease (MRD) as well as identifying mutations associated with resistance to therapy. This is anticipated to drive the demand for liquid biopsy from hospitals over the forecast period due to increasing adoption across oncology applications including breast, lung and colorectal cancers.
Liquid biopsies are also used for pre-operative planning in patients undergoing surgery or any other procedure where tissue needs sampling such as skin lesions or suspicious areas inside body cavities such as brain tumors or lymph nodes removal surgeries.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, such as Agilent Technologies, Inc.; Beckman Coulter; Danaher; and Roche Diagnostics Corporation. These companies are engaged in liquid biopsy research activities and have been developing innovative products for cancer detection that are adopted by clinicians across this region. In addition, these entities have been actively collaborating with regulatory bodies to obtain approval for their products in various countries. For instance, Agilent has collaborated with FDA on Liquid Biopsy Initiative (LBI) project which is a national program initiated by FDA to support cancer screening initiatives through quality data collection and sharing among U.S.-based providers (cancer screening programs).
Asia Pacific is expected to witness lucrative growth over the forecast period owing to increasing government spending on healthcare infrastructure coupled with rising awareness about early diagnosis of cancers among population especially those living in developed economies such as Japan.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the liquid tumor biopsy market. According to a study by the American Cancer Society, it is estimated that around 1,685,210 new cases of cancer will be diagnosed in 2017 in the U.S., and around 600,920 people will die from this disease. This number is expected to rise in the coming years due to factors such as aging population and lifestyle changes.
- Rising demand for personalized medicine: The growing demand for personalized medicine is another key growth driver for the liquid tumor biopsy market. Personalized medicine involves tailoring treatment according to an individual’s genetic makeup or other specific characteristics, which helps improve outcomes and reduce side effects. Liquid tumor biopsy plays a key role in personalized medicine by providing detailed information about tumors that can help guide treatment decisions.
- Advances in technology: Technological advances are helping drive growth in the liquid tumor biopsy market by making these tests more accurate and easier to use clinically. For example, recent advances have led to development of novel techniques such as microfluidics-based assays that can detect small amounts of DNA from tumors cells present in blood samples ( circulating free DNA or cfDNA). This allows detection of even very small tumors at an early stage when they are most treatable .
Scope Of The Report
Report Attributes
Report Details
Report Title
Liquid Tumor Biopsy Market Research Report
By Type
ctDNA, CTC
By Application
Clinical Laboratories, Hospital
By Companies
Abbott Laboratories, Bio-Rad Laboratories, F. Hoffmann-La Roche, Illumina, QIAGEN N.V., Thermo Fisher Scientific, Amoy Diagnostics, HaploX, Whole Genome Sequencing, Burning Rock Biotech
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
198
Number of Tables & Figures
139
Customization Available
Yes, the report can be customized as per your need.
Global Liquid Tumor Biopsy Market Report Segments:
The global Liquid Tumor Biopsy market is segmented on the basis of:
Types
ctDNA, CTC
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinical Laboratories, Hospital
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Abbott Laboratories
- Bio-Rad Laboratories
- F. Hoffmann-La Roche
- Illumina
- QIAGEN N.V.
- Thermo Fisher Scientific
- Amoy Diagnostics
- HaploX
- Whole Genome Sequencing
- Burning Rock Biotech
Highlights of The Liquid Tumor Biopsy Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- ctDNA
- CTC
- By Application:
- Clinical Laboratories
- Hospital
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Liquid Tumor Biopsy Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
A liquid tumor biopsy is a procedure that uses a needle to extract tissue from a tumor. The tissue is then examined to determine the type and stage of the cancer.
Some of the key players operating in the liquid tumor biopsy market are Abbott Laboratories, Bio-Rad Laboratories, F. Hoffmann-La Roche, Illumina, QIAGEN N.V., Thermo Fisher Scientific, Amoy Diagnostics, HaploX, Whole Genome Sequencing, Burning Rock Biotech.
The liquid tumor biopsy market is expected to register a CAGR of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Liquid Tumor Biopsy Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Liquid Tumor Biopsy Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Liquid Tumor Biopsy Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Liquid Tumor Biopsy Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Liquid Tumor Biopsy Market Size & Forecast, 2018-2028
4.5.1 Liquid Tumor Biopsy Market Size and Y-o-Y Growth
4.5.2 Liquid Tumor Biopsy Market Absolute $ Opportunity
Chapter 5 Global Liquid Tumor Biopsy Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Liquid Tumor Biopsy Market Size Forecast by Type
5.2.1 ctDNA
5.2.2 CTC
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Liquid Tumor Biopsy Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Liquid Tumor Biopsy Market Size Forecast by Applications
6.2.1 Clinical Laboratories
6.2.2 Hospital
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Liquid Tumor Biopsy Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Liquid Tumor Biopsy Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Liquid Tumor Biopsy Analysis and Forecast
9.1 Introduction
9.2 North America Liquid Tumor Biopsy Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Liquid Tumor Biopsy Market Size Forecast by Type
9.6.1 ctDNA
9.6.2 CTC
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Liquid Tumor Biopsy Market Size Forecast by Applications
9.10.1 Clinical Laboratories
9.10.2 Hospital
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Liquid Tumor Biopsy Analysis and Forecast
10.1 Introduction
10.2 Europe Liquid Tumor Biopsy Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Liquid Tumor Biopsy Market Size Forecast by Type
10.6.1 ctDNA
10.6.2 CTC
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Liquid Tumor Biopsy Market Size Forecast by Applications
10.10.1 Clinical Laboratories
10.10.2 Hospital
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Liquid Tumor Biopsy Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Liquid Tumor Biopsy Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Liquid Tumor Biopsy Market Size Forecast by Type
11.6.1 ctDNA
11.6.2 CTC
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Liquid Tumor Biopsy Market Size Forecast by Applications
11.10.1 Clinical Laboratories
11.10.2 Hospital
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Liquid Tumor Biopsy Analysis and Forecast
12.1 Introduction
12.2 Latin America Liquid Tumor Biopsy Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Liquid Tumor Biopsy Market Size Forecast by Type
12.6.1 ctDNA
12.6.2 CTC
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Liquid Tumor Biopsy Market Size Forecast by Applications
12.10.1 Clinical Laboratories
12.10.2 Hospital
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Liquid Tumor Biopsy Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Liquid Tumor Biopsy Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Liquid Tumor Biopsy Market Size Forecast by Type
13.6.1 ctDNA
13.6.2 CTC
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Liquid Tumor Biopsy Market Size Forecast by Applications
13.10.1 Clinical Laboratories
13.10.2 Hospital
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Liquid Tumor Biopsy Market: Competitive Dashboard
14.2 Global Liquid Tumor Biopsy Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Abbott Laboratories
14.3.2 Bio-Rad Laboratories
14.3.3 F. Hoffmann-La Roche
14.3.4 Illumina
14.3.5 QIAGEN N.V.
14.3.6 Thermo Fisher Scientific
14.3.7 Amoy Diagnostics
14.3.8 HaploX
14.3.9 Whole Genome Sequencing
14.3.10 Burning Rock Biotech
